A 4-year-old boy developed post-infectious glomerulonephritis (PIGN) and later atypical hemolytic uremic syndrome (aHUS), both of which affect the kidneys, but once doctors started treatment with the complement inhibitor Soliris (eculizumab), his blood problems resolved, his kidney function recovered, and he achieved long-term remission. “This case shows that…
News
A rare case of atypical hemolytic uremic syndrome (aHUS) developed after a kidney transplant in a young man and was successfully treated with Soliris (eculizumab), according to a case study. “The occurrence of [aHUS] following [kidney] transplantation is extremely uncommon and associated with adverse outcomes, often resulting in…
A teenage boy who was diagnosed in childhood with atypical hemolytic uremic syndrome (aHUS) was later found to also have Fabry disease and an inherited heart condition called hypertrophic cardiomyopathy — what researchers described as an “unusual trilogy” of rare diseases. The two additional genetic conditions were identified…
Treatment with Soliris (eculizumab), along with several immune-suppressing medications, was part of a treatment strategy that supported a woman with atypical hemolytic uremic syndrome (aHUS) in receiving a kidney donated from her mother — even though testing showed the two were not fully immunologically compatible. The case was…
Doctors successfully used a combination of Ultomiris (ravulizumab) and a blood pressure medication called sacubitril/valsartan to manage a case of atypical hemolytic uremic syndrome (aHUS) complicated by extremely high blood pressure. Researchers said it was the first reported case of the treatment combo being used to manage aHUS…
Prompt and intensive supportive care, which included plasma exchange and Soliris (eculizumab), successfully reversed organ failure and controlled atypical hemolytic uremic syndrome (aHUS) triggered by sepsis — a severe infection that can trigger widespread inflammation in the body — in a young…
Researchers have identified a potential gene therapy approach for atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), two kidney diseases driven by overactive complement activity, according to a new mouse study. In mouse models of both diseases, delivering the gene for the complement protein factor D to liver…
The safety and effectiveness of Ultomiris (ravulizumab-cwvz) as a maintenance therapy for children and adolescents with atypical hemolytic uremic syndrome (aHUS) remained unchanged even when the drug was administered at lower doses, not using the patient’s weight as a guide. That’s according to a new, small study that…
Leakage in an artificial heart valve appeared to trigger atypical hemolytic uremic syndrome (aHUS) in a 70-year-old woman who had no disease-related genetic mutations, a team of researchers noted in a new report, saying the case highlights the importance of a full examination for individuals suspected of having the…
Researchers reported that atypical hemolytic uremic syndrome (aHUS) is driven by abnormal activation of the alternative complement pathway, an immune response that’s independent of antibody activity, according to a study using endothelial cells that line blood vessels. These results challenge a recent report suggesting that aHUS…
Recent Posts
- aHUS symptoms differ in children, adults with same C3 variant
- Brothers with shared mutations develop different TMA patterns
- The days surrounding my aHUS diagnosis were a lonely time for me
- Delayed complement inhibition resolves pregnancy-related aHUS
- What comes next: Telling my story after an aHUS diagnosis
- Hidden rare mutations may help explain mystery cases of aHUS
- Soliris enables successful second kidney transplant: Case study
- The struggles of losing weight when you’re chronically ill
- COVID-19 triggers aHUS in man following kidney transplant
- Heart complications were a puzzling part of my aHUS journey